PTK787/ZK 222584 (vatalanib)

vatalanib · Novartis

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for PTK787/ZK 222584 (vatalanib), covering 2016-07-01 to 2016-07-01. Get the full timeline:

Most recent: Clinical Trial Update: PTK787/ZK 222584 in Treating Patients With Unresectable Malignant Mesothelioma [Phase 2]